Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme

被引:47
作者
Holtkamp, Nikola
Ziegenhagen, Nicolas
Malzer, Elke
Hartmann, Christian
Giese, Alf
von Deimling, Andreas
机构
[1] Heidelberg Univ, Dept Neuropathol, D-69120 Heidelberg, Germany
[2] Univ Med Berlin, Charite, Inst Neuropathol, D-13353 Berlin, Germany
[3] Univ Gottingen, Dept Neurosurg, D-37073 Gottingen, Germany
关键词
gene amplification; glioblastoma; KDR; KIT; PDGFRA;
D O I
10.1215/15228517-2007-009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A subset of glioblastomas (GBMs) carry gene amplifications on chromosomal segment 4q12. To characterize this amplicon in detail, we analyzed a set of 100 samples consisting of 65 GBMs, 10 WHO grade III astrocytomas, 12 oligodendrogliomas, and 13 glioma cell cultures. We applied multiplex ligation-dependent probe amplification to determine the gene dosage of PDGFRA, KIT, and KDR and the flanking genes USP46, RASL11B, LNX1, CHIC2, SEC3L1, and IGFBP7. The amplicon was highly variable in size and copy number and extended over a region of up to 5 Mb. Amplifications on 4q12 were observed in 15% of GBMs and 23% of GBM cell cultures but not in 22 other gliomas. We analyzed transcription and translation of some genes within this amplicon. Gene amplification generally correlated with high transcript levels but did not necessarily result in increased protein levels. However, we detected frequent expression of proteins encoded by PDGFRA, KIT, and KDR in GBMs and GBM cell cultures independent of the amplification status. Future treatment of GBM patients may include drugs targeting multiple kinases that are encoded by genes on chromosomal segment 4q12.
引用
收藏
页码:291 / 297
页数:7
相关论文
共 21 条
[1]  
Carroll RS, 1999, CANCER-AM CANCER SOC, V86, P1335, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1335::AID-CNCR32>3.0.CO
[2]  
2-Z
[3]  
FLEMING TP, 1992, CANCER RES, V52, P4550
[4]   Immunohistochemical analysis of platelet-derived growth factor receptor-α, -β, c-kit, c-abl, and arg proteins in glioblastoma:: Possible implications for patient selection for imatinib mesylate therapy [J].
Haberler, C ;
Gelpi, E ;
Marosi, C ;
Rössler, K ;
Birner, P ;
Budka, H ;
Hainfellner, J .
JOURNAL OF NEURO-ONCOLOGY, 2006, 76 (02) :105-109
[5]   PDGFR-a in 1p/19q LOH oligodendrogliomas [J].
Hartmann, C ;
Xu, XD ;
Bartels, G ;
Holtkamp, N ;
Gonzales, IA ;
Tallen, G ;
Von Deimling, A .
INTERNATIONAL JOURNAL OF CANCER, 2004, 112 (06) :1081-1082
[6]  
Hermanson M, 1996, CANCER RES, V56, P164
[7]   Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity [J].
Holtkamp, N ;
Okuducu, AF ;
Mucha, J ;
Afanasieva, A ;
Hartmann, C ;
Atallah, I ;
Estevez-Schwarz, L ;
Mawrin, C ;
Friedrich, RE ;
Mautner, VF ;
von Deimling, A .
CARCINOGENESIS, 2006, 27 (03) :664-671
[8]   Amplification of genes encoding KIT, PDGFRα and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme [J].
Joensuu, H ;
Puputti, M ;
Sihto, H ;
Tynninen, O ;
Nupponen, NN .
JOURNAL OF PATHOLOGY, 2005, 207 (02) :224-231
[9]   RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes [J].
Kao, Jessica ;
Pollack, Jonathan R. .
GENES CHROMOSOMES & CANCER, 2006, 45 (08) :761-769
[10]   A rare case of acute myeloid leukemia with a CHIC2-ETV6 fusiongene and multiple other molecular aberrations [J].
Kuchenbauer, F ;
Schoch, C ;
Holler, E ;
Haferlach, T ;
Hiddemann, W ;
Schnittger, S .
LEUKEMIA, 2005, 19 (12) :2366-2368